As of October 22, 2026, Grifols SA ADR (GRFS) trades at $7.44. No model fair value is published for GRFS. GRFS reports its financial statements in EUR. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar.
Source: Equity Rank — GRFS valuation (data as of 2026-10-22). The full page shows the company’s fundamental profile and earnings data.
Reported EPS came in above the analyst estimate in 1 of the last 8 reports. The median share-price change across a report, in either direction, was 3.8%.
| Report | EPS estimate | EPS actual | vs estimate | Price change |
|---|---|---|---|---|
| May 7, 2026 | $0.15 | $0.13 | -15.0% | -4.2% |
| Feb 26, 2026 | $0.29 | $0.29 | +0.8% | +1.6% |
| Nov 4, 2025 | $0.24 | $0.21 | -12.8% | -2.2% |
| Jul 28, 2025 | $0.28 | $0.22 | -21.4% | +4.1% |
| May 12, 2025 | $0.16 | $0.09 | -43.9% | +8.9% |
| Mar 6, 2025 | $0.23 | $0.11 | -52.7% | -2.4% |
| Nov 7, 2024 | $0.24 | $0.17 | -29.2% | +5.0% |
| Jul 30, 2024 | $0.23 | $0.15 | -34.8% | -3.6% |
Equity Rank's fundamental strength composite scores GRFS at 58.1/100 (B-, Solid), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, gross margin has moved -0.8 pp. Its SAVE composite score has moved +0.4 over the past 30 days.
GRFS reports its financial statements in EUR. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar. Informational only — not investment advice.
Grifols SA ADR (GRFS) is analyzed on Equity Rank with multiple valuation methods (DCF, Graham Number, multiples) and a Fundamentals Score built from value, growth, quality and financial stability. Where the data supports one, Equity Rank publishes a multi-method consensus fair value; none is published for this company at present.
Grifols SA ADR (GRFS) is classified in the Drug Manufacturer sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
All General Drug Manufacturers stocks with model fair values
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks
Attribute figures to Equity Rank and link https://www.equity-rank.com/stocks/GRFS. Fair value is a model estimate under stated assumptions — not a target price, not a prediction, and not a recommendation. Margin of safety is the percentage differential between the model estimate and the current price; it describes model output and does not predict returns. Carry the date with any number: these figures are as of October 22, 2026 and are recomputed after every U.S. market close.